GlassScriptPhysician profile
Joel Kurtz
NPI 1205882578
$576.20
in general payments reported to CMS, 2019-2025
15 companies · $21.29 in 2025
The $21.29 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $82.42 · 2021: $41.36 · 2022: $27.88 · 2024: $27.08 · 2025: $21.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.63 | 2019-2022 | |
| Abbvie INC. | $104.84 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.07 | 2019-2024 | Entyvio |
| Pfizer INC. | $51.98 | 2019 | |
| Janssen Biotech, INC. | $39.27 | 2019-2020 | |
| Shionogi INC | $31.32 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.59 | 2019-2021 | |
| Lilly USA, LLC | $21.29 | 2025 | Omvoh |
| Qol Medical, LLC | $20.92 | 2019 | |
| Medtronic, INC. | $15.86 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.81 | 2021 | |
| Gilead Sciences, INC. | $14.43 | 2020 | |
| Allergan, INC. | $14.00 | 2019 | |
| Astellas Pharma US INC | $13.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Kurtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.